Leading orthopaedic surgeons and pharmacologists have confirmed their backing for chondroitin sulphate supplements as a way of managing joint discomfort, according to one supplement manufacturer.
Experts and doctors attending the American Academy of Orthopedic Surgeons' 70th Annual Meeting in New Orleans in February discussed recent clinical evidence showing how low molecular weight (LMW) chondroitin sulphate is safe and effective for reducing joint pain.
Reporting on the proceedings, US nutraceutical manufacturer Nutramax Laboratories, which makes the joint health supplement CosaminDS, said that doctors confirmed scientific findings backing the efficacy of low molecular weight (LMW) chondroitin sulphate.
They noted that joint pain may be related to changes in the structure and function of joint cartilage but products with LMW chondroitin sulphate can actually modify structural changes in addition to reducing discomfort. The nutrient can slow the progression of changes in the structure and function of joint cartilage, according to Nutramax.
Also LMW chondroitin sulphate is not known to interact with prescription medicines, said the doctors, and it does not affect the gastro-intestinal system like other drugs. Studies have shown that the supplement is absorbed by the body whereas it is unknown if other forms of chondroitin sulphate are even absorbed.
There is however great variation among different products on the market. Low molecular weight chondroitin sulphate has been available for some time in Europe as a pharmaceutical. Spanish pharmaceutical company Bioiberica makes a 95 per cent pure LMW chondroitin sulphate, claimed to have been proven effective, absorbable and safe, and used in the CosaminDS brand.